Methyl Alcohol

Methyl Alcohol

SCHEMBL7668985

CCCCCCC(CO)C(=O)OCC.CO

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 2/20 0.51
CA2 P00918 2/20 0.47
LMNA P02545 2/20 0.45
ZDHHC7 Q9NXF8 1/20 0.44
CA1 P00915 1/20 0.43
GRIK1 P39086 2/20 0.42
GRIK2 Q13002 2/20 0.42
GPR84 Q9NQS5 3/20 0.41
FFAR1 O14842 1/20 0.41
KDM4E B2RXH2 1/20 0.41
DUSP3 P51452 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPT P10636 2/20 0.41
MAPK1 P28482 1/20 0.41
LCK P06239 1/20 0.40
PPARD Q03181 1/20 0.40
ZDHHC20 Q5W0Z9 1/20 0.40
ZDHHC2 Q9UIJ5 1/20 0.40
SLC1A2 P43004 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL319980 0.98 CPB2 (0.53) CPB2CA2LMNAZDHHC7CA1
SCHEMBL277442 0.98 CPB2 (0.53) CPB2CA2LMNAZDHHC7CA1
Ammonia Solution, Strong SCHEMBL5121318 0.96 CPB2 (0.51) CPB2CA2LMNAZDHHC7CA1
SCHEMBL3845206 0.96 CPB2 (0.50) CPB2CA2LMNAZDHHC7CA1
Acetic Acid SCHEMBL3260364 0.93 CPB2 (0.49) CPB2CA2LMNAZDHHC7CA1
Ethyl Acetate SCHEMBL1279632 0.91 CPB2 (0.47) CPB2CA2LMNAZDHHC7CA1
Ethyl Acetate SCHEMBL5064725 0.91 CPB2 (0.47) CPB2CA2LMNAZDHHC7CA1
SCHEMBL3176263 0.90 CA2 (0.52) CPB2CA2CA1KDM4EDUSP3
Ethyl Acetate SCHEMBL17699277 0.89 CPB2 (0.45) CPB2CA2LMNAZDHHC7GRIK1
Ethyl Acetate SCHEMBL17005456 0.89 CPB2 (0.45) CPB2CA2LMNAZDHHC7GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed